Margaret Esiri - Selected Publications#

Ferguson B, Matyszak MK, Esiri MM, Perry VH (1997). Axonal damage in acute multiple sclerosis lesions. Brain. 120:393-9

Nagy Zs, Esiri MM (1998). Neuronal cyclin expression in the hippocampus in temporal lobe epilepsy. Exp. Neurol. 150:240-47.

Highley JR, Esiri MM, McDonald B, Cortina-Borja M, Heron BM, Crow TJ (1999). The size and fibre composition of the corpus callosum with respect to gender and schizophrenia: a post mortem study. Brain 122:99-110.

Esiri MM, Matthews F, Brayne C, Ince P for CFAS (2001). Pathological correlates of late onset dementia in a multi-centre community based population in England and Wales. Lancet 357:169-75.

Medana I and Esiri MM (2003). Axonal damage: a key predictor of outcome in human CNS diseases. Brain 126:515-30. 251.

Esiri MM, Perl D (2006). Oppenheimer’s Diagnostic Neuropathology 3rd Edition. Arnold, London (566 pp).(Shortlisted for illustrated medical textbook (see awards above)

Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L (2008). Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 172:146-55.

Esiri MM, Chance S, Joachim C, Warden D, Smallwood A, Sloan C, Christie S, Wilcock GK, Smith AD (2015) Cerebral amyloid angiopathy, subcortical white matter disease and dementia: literature review and study in OPTIMA. Brain Pathol 25: 51-62.

Esiri MM, Wilcock GK (2016). Some questions posed about the prevention and treatment of Alzheimer’s disease. Frontiers in Clinical Drug Research – Alzheimer Disorders: Vol 4 Chapter 3 pp 128-75

Munoz U et al Main role of antibodies in demyelination and axonal damage in multiple sclerosis. Cell Mol Neurobiol (2021) Feb 24.doi: 10/1007/s10571-021-01059-6